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CCL21 expression by lymphatic endothelial cells (LECs) is essential for migration of CCR7þ immune cells from
skin to regional lymph nodes (LNs). We investigated the importance of mitogen-activated protein kinase
(MAPK) signaling in CCL21 expression by ECs in vitro and in vivo. Normal human dermal lymphatic
microvascular ECs (HMVEC-dLy) stimulated in vitro with oncostatin M (OSM) expressed high amounts of CCL21
mRNA. CCL21 protein expression by HMVEC-dLy was also markedly increased by OSM compared with
unstimulated cultures. Marked phosphorylation of MAPK 44/42 was detected in HMVEC-dLy stimulated by OSM.
CCL21 expression by HMVEC-dLy was blocked by a JAK inhibitor 1, JAK3 inhibitor, and U0126 (a MAPK kinase
inhibitor) in vitro, all of which blocked phosphorylation of MAPK 44/42. In addition, injection of U0126 into
murine skin significantly decreased CCL21 mRNA and protein expression. Moreover, injection of U0126 before
sensitization decreased migration of dendritic cells to draining LNs and decreased contact hypersensitivity
responses. In summary, these results suggest that the MAPK pathway is important for CCL21 expression by
LECs in vitro and in vivo. Blocking MAPK signaling within skin may offer a novel approach to treatment of
inflammatory skin diseases.
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INTRODUCTION
CCL21 and its receptor, CCR7, are critically involved in the
migration of antigen (Ag)-presenting dendritic cells (DCs;
Forster et al., 1999; Gunn et al., 1999; Saeki et al., 1999) from
peripheral tissues to draining lymph nodes (LNs) via afferent
lymphatic vessels. The expression of CCL21 is restricted to
high endothelial venules, stromal cells in secondary lymphoid
organs (Gunn et al., 1998), and lymphatic vessels in multiple
organs including skin (Saeki et al., 1999). DCs from CCR7-
deficient mice are strikingly impaired in their ability to enter
lymphatic vessels and migrate to secondary lymphoid organs
(Forster et al., 1999; Ohl et al., 2004). Moreover, there is a
marked reduction of naive T cells and disorganization of the
DC network within LN of mice homozygous for the paucity of
LN T-cell (plt) mutation, which is characterized by the lack of
CCL21 expression in LN (Nakano et al., 1998; Gunn et al.,
1999; Fagarasan et al., 2000). Collectively, these data suggest
that CCL21 and CCR7 are vital for normal migration and
retention of specific T cells and DCs within secondary
lymphoid organs.
Oncostatin M (OSM) is a member of the IL-6 family of
cytokines with pleiotropic biological effects (Tanaka and
Miyajima, 2003). Produced by a number of inflammatory
cells, including activated T cells, monocytes, and DCs (Suda
et al., 2003; Tanaka and Miyajima, 2003), OSM can exert
both pro- and anti-inflammatory effects, depending on the
model system examined (Pelletier and Martel-Pelletier,
2003). Endothelial cells (ECs) express high numbers of OSM
receptors, and OSM has been shown to upregulate expression
of several cytokines and chemokines in human umbilical
vein endothelial cell (Modur et al., 1997). Furthermore, OSM
is a potent growth factor for AIDS-associated Kaposi’s
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sarcoma (Miles et al., 1992; Nair et al., 1992; Murakami-Mori
et al., 1995), a tumor comprised morphologically of cells
with the characteristics of lymphatic ECs (LECs; Beckstead
et al., 1985).
In a previous study, we revealed that OSM enhanced
CCL21 expression by microvascular EC (MEC) and increased
the efficiency of DC trafficking to LNs (Sugaya et al., 2006). It
was somewhat surprising that MEC could be stimulated to
produce CCL21 by OSM because CCL21 expression is
associated with lymphatic vessels in vivo (Gunn et al.,
1998). LEC differ from blood vascular EC by expressing a
characteristic set of proteins, including lymphatic vascular
EC-1 (LYVE)-1, podoplanin, vascular endothelial growth
factor receptor 3 (VEGFR3), and Prox-1 (Jackson, 2003).
Interestingly, human dermal MEC isolated and cultured from
neonatal (Cardones et al., 2006) and adult skin (Kriehuber
et al., 2001; Podgrabinska et al., 2002) are heterogeneous,
with a significant population of cells expressing lymphatic-
associated proteins, including podoplanin and LYVE-1.
In this current report, we revealed that OSM treatment of
primary human dermal MEC led to an enhanced expression
of a large number of LEC-specific genes including CCL21. We
also showed that purified LEC stimulated with OSM in vitro
expressed high amounts of CCL21 mRNA and protein via
activation of the mitogen-activated protein kinase (MAPK) 44/
42 pathway. MAPK/extracellular signal-regulated kinase
kinase (MEK) inhibition within skin before hapten sensitiza-
tion decreased migration of DCs to draining LNs and
decreased contact hypersensitivity (CHS) responses.
RESULTS
OSM stimulates expression of LEC-specific genes in primary
human dermal MEC
As CCL21 expression was previously believed to be specific
for LECs (when compared with blood ECs), we asked the
question as to whether OSM could stimulate expression of
other genes preferentially expressed in LECs. Using comple-
mentary DNA microarray analyses, we found that primary
human dermal MEC stimulated with 100 ng ml1 of OSM for
2 days upregulated expression of CCL21 along with four other
genes classically associated with LECs (Table 1). Specifically,
mRNA levels for VEGFR3, LYVE-1, podoplanin, and Prox-1
were all markedly upregulated in human dermal MEC
exposed to OSM (Table 1). Many other less well-known
genes (82 in all) that are preferentially expressed in lymphatic
endothelium when compared with blood vessel endothelium
(Hong et al., 2004; Podgrabinska et al., 2002) were also
upregulated (Supplementary Table S1 online). The two
complementary DNA microarray experiments revealed strik-
ingly similar results, confirming the reproducibility of our
findings. To assess the effects of OSM, IL-6, or IL-31 on
differentiation of human dermal MEC, we also performed
quantitative RT-PCR using mRNA from MEC stimulated with
OSM, IL-6, or IL-31. Consistent with the microarray experi-
ments and our previous report, OSM treatment strongly
increased CCL21 mRNA expression in MEC (Supplementary
Figure S1 online). Moreover, OSM or IL-6 treatment
increased LYVE-1 mRNA and decreased VEGFR1 mRNA
expression (Supplementary Figure S1 online). These results
suggested that OSM and IL-6 could cause preferential
differentiation from MEC into LEC. To clarify the effects of
OSM, IL-6, or IL-31 on terminally differentiated LEC, which
was more relevant to in vivo situation, we decided to use
normal human dermal lymphatic MECs (HMVEC-dLy),
purified LEC expressing podoplanin (495%), for the follow-
ing experiments.
CCL21 mRNA and protein expression by OSM-treated LEC
To determine the effects of IL-6 family cytokines including on
LEC in vitro, we treated HMVEC-dLy with OSM, IL-6, or IL-31
and measured mRNA levels of CCL21 by quantitative real-
time RT-PCR (Figure 1a). Under serum-free conditions,
upregulation of CCL21 mRNA was detected in HMVEC-dLy
at 48 hours as well as 72 hours after addition of OSM (10 and
100 ng ml1), but not after addition of other cytokines (IL-6
and IL-31; Figure 1a). We next treated HMVEC-dLy with
OSM (100 ng ml1) and measured protein levels of CCL21
(Figure 1b). Under serum-free conditions, supernatant CCL21
levels of HMVEC-dLy were increased by stimulation with
OSM at 72 hours (Figure 1b). Thus, OSM treatment increased
transcriptional and translational expression of CCL21 in
human LEC.
OSM induces phosphorylation of STAT3 and MAPK 44/42
IL-6 family cytokines including OSM have previously been
shown to stimulate several signaling pathways, such as
MAPK, signal transducers and activators of transcription 3
(STAT3), and phosphoinositide-3 kinase/Akt (acutely trans-
forming retrovirus AKT8 in rodent T cell lymphoma; El
Mabrouk et al., 2007; Lee et al., 2007; Zhang et al., 2008). To
determine whether these pathways were involved in CCL21
expression in OSM-stimulated LEC, we examined phosphor-
ylation of MAPK 44/42, STAT3, and Akt. Using HMVEC-dLy,
we found only slightly detectable MAPK 44/42 phosphorylation
and no detectable STAT3 and Akt phosphorylation in
Table 1. OSM increases expression of classic LEC-
specific genes in dermal MEC
Gene Primer pair Experiment 1 Experiment 2
LYVE-1 219059_s_at 6.9 4.7
220037_s_at 9.8 15.6
VEGFR3 210316_at 3.3 4.0
Podoplanin 204879_at 2.5 5.9
208233_at 2.2 2.5
221898_at 13.9 30.1
Prox-1 207401_at 6.6 5.9
228656_at 10.1 8.8
242119_at 1.8 2.2
CCL21 204606_at 10.4 5.3
Abbreviations: LEC, lymphatic endothelial cell; LYVE-1, lymphatic
vascular EC-1; MEC, microvascular EC; OSM, oncostatin M; VEGFR3,
vascular endothelial growth factor receptor 3.
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unstimulated cells (Figure 2a and data not shown). By
contrast, incubation with 100 ng ml1 OSM, but not IL-6 or
IL-31, for 15 minutes as well as 30 minutes markedly induced
MAPK 44/42 phosphorylation in these cells (Figure 2a).
Incubation with 100 ng ml1 OSM and IL-6, but not IL-31, for
15 or 30 minutes markedly induced STAT3 phosphorylation
in these cells (Figure 2a). Incubation with 100 ng ml1 OSM,
but not IL-6 or IL-31, for 15 as well as 30 minutes only slightly
induced Akt phosphorylation in these cells (data not shown).
Thus, the MAPK 44/42 pathway seems most important for
CCL21 expression in OSM-treated human LEC.
CCL21 expression by LEC is blocked by inhibition of JAK
and MEK
To investigate signaling pathways important for CCL21
expression in OSM-stimulated LEC, we used JAK inhibitor
1, an inhibitor of JAK family kinases, JAK3 inhibitor, and
U0126, a MEK inhibitor. MAPK 44/42 phosphorylation in
HMVEC-dLy was blocked highly by U0126, moderately by
JAK inhibitor 1, and slightly by JAK3 inhibitor (Figure 2b). JAK
inhibitor 1, but not JAK3 inhibitor or U0126, blocked
phosphorylation of STAT3 in HMVEC-dLy (Figure 2b).
CCL21 protein expression by OSM-treated HMVEC-dLy was
blocked highly by U0126, moderately by JAK inhibitor 1, and
slightly by JAK3 inhibitor (Figure 2c). The suppression of
CCL21 protein expression correlated with degree of blockade
of MAPK 44/42 phosphorylation, but not STAT3 phosphor-
ylation, suggesting that CCL21 expression by HMVEC-dLy is
mainly dependent on MAPK signaling.
MEK inhibition within murine skin decreases CCL21 mRNA
and protein expression
To assess the importance of MAPK signaling in CCL21
expression in vivo, we injected the ears of C57BL/6 mice with
DMSO or 100mM U0126, a MEK inhibitor, and extracted total
skin RNA 24 hours later. Quantitative real-time RT-PCR was
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Figure 1. Normal human dermal lymphatic microvascular endothelial cells (HMVEC-dLy) upregulate mRNA and protein for CCL21 upon oncostatin M (OSM)
stimulation. (a) Following stimulation of HMVEC-dLy in no serum for 24, 48, or 72 hours with OSM, IL-6, or IL-31 (1, 10, or 100 ng ml1), CCL21 mRNA
expression was quantified by real-time RT-PCR. Results are representative of three experiments with similar findings. (b) HMVEC-dLy were stimulated with OSM
(100 ng ml1) for 48 or 72 hours, after which supernatants were collected for ELISA-based measurement of CCL21 concentration. Values shown represent means
and SDs of three separate experiments. **Po0.01. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.
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performed to measure CCL21, CCR7, and LYVE-1 mRNA
expression relative to glyceraldehyde-3-phosphate dehydro-
genase (GAPDH). CCL21 mRNA expression was decreased
by U0126 injection, whereas CCR7 and LYVE-1 mRNA
expression remained unchanged (Figure 3a and data not
shown). We also lysed the ears using homogenizer 24 hours
later, and western blotting was performed to detect CCL21
protein expression. CCL21 protein expression was decreased
by U0126 injection (Figure 3b). Therefore, U0126 treatment
decreased transcriptional and translational expression of
CCL21 in mouse skin.
MEK inhibition within murine skin decreases migration of DCs
to draining LNs
Based on the data above, we predicted that intradermal
injection of skin with U0126 would result in decreased DC
migration from peripheral tissues (i.e., skin) to draining LN
in vivo, presumably by decreasing expression of CCL21 by
LEC. To test this hypothesis, we painted FITC onto murine
ears, followed by injecting U0126 or DMSO, and after
24 hours, draining LNs were collected for flow cytometry. In
this experiment, only migratory DCs were stained strongly
positive for major histocompatibility complex class II,
whereas resident DCs were lost in major histocompatibility
complex class II-negative population together with B cells
(Figure 3c). The total cell numbers in LNs were not
statistically different between the two groups. After treatment
with U0126, the frequency of migratory DCs and Ag-bearing
migratory DCs in draining LNs was decreased as expected
(Figure 3d).
MEK inhibition within skin before hapten sensitization
decreases CHS responses
To determine whether blocking MAPK signaling within skin
can decrease CHS responses, we injected the ears of C57BL/6
mice with DMSO or 100mM U0126 1 day before sensitization
or elicitation. Injection with U0126 1 day before sensitization
significantly decreased CHS responses compared with DMSO
treatment (Figure 4a). In contrast, when U0126 was injected
1 day before elicitation, CHS responses were not impaired
(Figure 4b). Mice without sensitization did not show ear
swelling as expected (data not shown). We also evaluated
CHS responses histopathologically. The ear swelling and
cellular infiltration 24 hours after the challenge were less
prominent in mice injected with U0126 1 day before
sensitization compared with mice injected with DMSO
(Figure 4c). Therefore, blocking MAPK signaling within skin
during the sensitization phase can decrease CHS responses.
Anti-CCL21 antibody injection before hapten sensitization or
challenge decreases CHS responses
To assess specific CCL21 effect, we next injected the ears of
C57BL/6 mice with phosphate-buffered saline (PBS),
20 mg ml1 anti-mouse CCL21 antibody (Ab), or 25 mg ml1
recombinant mouse CCL21 1 day before sensitization or
elicitation. As expected, injection with anti-mouse CCL21 Ab
1 day before sensitization significantly decreased CHS
responses compared with PBS treatment (Figure 4d). On the
contrary, injection with recombinant mouse CCL21 did not
increase CHS response, suggesting that CCL21 expression
in the ear was sufficient (Figure 4d). Surprisingly, injection
with anti-mouse CCL21 Ab 1 day before elicitation also
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Figure 2. Oncostatin M (OSM) induces MAPK 44/42 phosphorylation in
normal human dermal lymphatic microvascular endothelial cells (HMVEC-
dLy), which correlated with CCL21 expression. (a) Induction of MAPK 44/42
and signal transducers and activators of transcription 3 (STAT3)
phosphorylation in HMVEC-dLy stimulated with 100 ng ml1 OSM. Induction
of STAT3 phosphorylation in HMVEC-dLy stimulated with 100 ng ml1 IL-6.
Induction of neither phosphorylation stimulated with 100 ng ml1 IL-31. A
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different degrees. Phosphorylation of STAT3 was blocked by JAK inhibitor 1.
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and SEs of three separate experiments. *Po0.05.
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significantly decreased CHS responses compared with PBS
treatment (Figure 4e). Therefore, blocking CCL21 during
either sensitization or elicitation phase suppressed CHS, but
adding recombinant CCL21 did not affect CHS.
DISCUSSION
In this study, we found that OSM enhanced CCL21 mRNA
and protein expression by HMVEC-dLy, purified LEC
(Figure 1). We then demonstrated that OSM induced high
levels of phosphorylation of MAPK 44/42 and STAT3 in
HMVEC-dLy (Figure 2a), which is consistent with previous
studies using a variety of cells (Thoma et al., 1994; Stancato
et al., 1997). We also showed that IL-6 induced enhanced
phosphorylation of STAT3, but not MAPK44/42, and that IL-
31 did not induce phosphorylation of STAT3 or MAPK44/42
in HMVEC-dLy (Figure 2a). OSM, IL-6, and IL-31 are
members of the IL-6 family of cytokines, whose receptors
are composed of different subunits. OSM receptor is a
complex of OSMR and gp130, IL-6 receptor is a complex
of IL-6R and gp130 (Tanaka and Miyajima, 2003), and
IL-31 receptor is a complex of the OSMR and IL-31RA
(Zhang et al., 2008). The differences in receptors may
explain the different signaling pathways activated by these
cytokines.
We next showed that treatment of a MEK inhibitor
downregulated CCL21 expression and decreased migration
of DCs and Ag-bearing DCs to LNs in vivo (Figure 3). CCL21
and CCR7 interaction has been reported to be critically
involved in the migration of Ag-presenting DCs (Forster et al.,
1999; Gunn et al., 1999; Saeki et al., 1999). Importantly, our
results elucidate the underlying molecular regulation in-
volved in CCL21-mediated DC migration. We have also
shown that blocking MAPK signaling or neutralization of
CCL21 within skin before sensitization can decrease CHS
(Figures 4a, c and d), which are consistent with previous
reports (Engeman et al., 2000). In both CCR7-deficient and plt
mice, where CCL21–CCR7 interactions were abrogated,
T cells and CHS responses were increased (Schneider et al.,
2007; Nakano et al., 2009). In these mice, however,
CCL19–CCR7 interactions were also abrogated. Moreover,
defect in CCL21–CCR7 interactions from birth may have
caused immunological changes in these mice. Interestingly,
neutralization of CCL21 within skin before elicitation
decreased CHS (Figure 4e), suggesting that CCL21 expression
was also important in the elicitation phase. On the contrary,
blocking MAPK signaling within skin before elicitation did
not affect CHS responses. The effects of U0126 injected into
the skin cannot be expected to be limited to CCL21
expression by LECs. U0126 might have abrogated regulatory
mechanisms for CHS responses. In addition, we injected
DMSO as a negative control in experiments using U0126,
which was dissolved in DMSO. Injection of DMSO into
the elicitation site may have induced MPAK-independent
ear-swelling responses, increasing ear thickness of baseline
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Representative means and SEMs of six mice of two experiments. *Po0.05. (b) CCL21 protein expression relative to b-actin. Means and SEMs of three mice of
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(day 0), which may account for no significant differences
between DMSO and U0126.
Our data and those of others have suggested that CCL21
expression in dermal LECs is associated with DC migration
and CHS responses (Engeman et al., 2000). Migration of
dermal DCs into the draining LNs also has a central role in
various types of skin inflammation. CCL21 expression is
upregulated in the skin lesions of psoriasis and lichen planus,
as well as allergic and irritant contact dermatitis (Eberhard
et al., 2004; Serra et al., 2004; Manzo et al., 2007). Blocking
MAPK signaling or neutralization of CCL21 can be a, to our
knowledge, previously unreported approach to the treatment
of these diseases. The MAPK signaling pathway has been a
major clinical focus in oncology research, and many
inhibitors targeting this pathway have been pursued (Wang
et al., 2007; Wong, 2009). Several oral MEK inhibitors, such
as PD0325901 and AZD6244, have been evaluated in
clinical trials (Adjei et al., 2008; Haura et al., 2010; LoRusso
et al., 2010). Other than cancers, MEK inhibitors can
effectively treat rheumatoid arthritis, a systemic autoimmune
inflammatory disease (Thiel et al., 2007). Inflammatory skin
diseases, including contact dermatitis, psoriasis, and lichen
planus, can be treated with these inhibitors. Considering the
side effects reported in the clinical trials, topical application
of MEK inhibitors is an ideal treatment. So far, MEK inhibitors
have been used topically only in mouse models (Jaffee et al.,
2000; Leng et al., 2009). We hope safe and effective topical
MEK inhibitors for human skin diseases will be developed in
the near future.
DCs have the potential to overcome tumor tolerance and
induce antitumor immunity when loaded with tumor Ag
(Sheng et al., 2005). It is important to understand precise
conditions on which DCs migrate to the draining LNs most
efficiently because this step is critical for DC-based im-
munotherapy against cancers. Our results are consistent with
previous reports describing that CCR7 and CCL21 are the
dominant mediators in the mobilization of DCs to LNs via
lymphatics (Forster et al., 1999; Saeki et al., 1999; MartIn-
Fontecha et al., 2003). Indeed, CCL21 expression in tumor
microenvironment or intratumoral CCL21 administration
inhibited tumor growth (Turnquist et al., 2007; Yousefieh
et al., 2009). Our study suggests that enhanced CCL21
expression through activation of MAPK pathways in tumor
microenvironment could be a, to our knowledge, previously
unreported approach to the treatment of cancers.
MATERIALS AND METHODS
Animals, cell lines, and reagents
C57BL/6 mice were purchased from SLC Japan (Hamamatsu, Japan).
All mice were free of pathogenic bacteria and viruses, as determined
by Ab screening and routine histological analysis of organs and
tissues. All experiments were performed using mice between 8 and
14 weeks of age. All studies and procedures were approved by the
Animal Experiment Committee of the Graduate School of Medicine
of the University of Tokyo, guided by the Bioscience Committee of
the University of Tokyo. Human dermal MEC were purchased from
the Endothelial Cell Core Facility (Department of Dermatology,
Emory University School of Medicine, Atlanta, GA). HMVEC-dLy
were purchased from Takara Bio (Shiga, Japan). Recombinant human
OSM, IL-6, IL-31, anti-mouse CCL21-neutralizing Ab, and recombi-
nant mouse CCL21 were purchased from R&D systems (Minneapo-
lis, MN). Abs against MAPK 44/42, phosphorylated MAPK 44/42,
Akt, phosphorylated Akt, STAT3, and phosphorylated STAT3 for
western blotting were obtained from Cell Signaling Technology
(Boston, MA). U0126 was also purchased from Cell Signaling
Technology, and JAK inhibitor 1 and JAK3 inhibitor were from
Calbiochem (Gibbstown, NJ) and were dissolved in DMSO before
use. Abs against mouse CCL21 and b-actin for western blotting were
obtained from R&D systems. PE-conjugated anti-MHC class II for
flow cytometry was purchased from Pharmingen (San Diego, CA).
Complementary DNA microarray experiments and analyses
Primary human dermal MEC were cultured for 4 (experiment no. 1)
or 6 passages (experiment no. 2). Two days after passaging cells,
media was replaced with fresh media with or without 100 ng ml1 of
OSM. Twenty-four hours later, cells were lysed, and total RNA was
isolated with an RNeasy extraction kit (Qiagen, Valencia, CA) and
assessed for integrity. Complementary DNA synthesis, hybridization
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Figure 4. Impaired contact hypersensitivity response by injection of a
mitogen-activated protein kinase/extracellular signal-regulated kinase
kinase inhibitor or anti-CCL21-neutralizing antibody (Ab) 1 day before
sensitization. DMSO or U0126 (100 mM, 20 ml) was injected into the ear 1 day
before sensitization (a) or elicitation (b). (c) Hematoxylin and eosin staining of
the ears of mice injected with DMSO or U0126 1 day before sensitization
(24 hours after challenge). Representative pictures of three mice
(bar¼ 100 mm). Phosphate-buffered saline (PBS), recombinant CCL21
(25mg ml1), or anti-CCL21-neutralizing Ab (20 mg ml1) was injected into the
ear 1 day before sensitization (d) or elicitation (e). Means and SEMs (n¼5–9).
*Po0.05.
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to HG_U133 plus 2.0 arrays (Affymetrix, Santa Clara, CA), and signal
intensity normalization were performed at the OHSU microarray
core facility. Image processing and expression analyses were
performed using GCOS v1.2 software (Affymetrix).
Quantitative RT-PCR to assess the effects of OSM IL-6 and IL-31
on differentiation of primary human dermal MEC
Primary human dermal MEC were stimulated with OSM, IL-6, or
IL-31 (100 ng ml1) for 24 hours, and total RNA was prepared by
using TRIZOL Reagent (Invitrogen, Carlsbad, CA). Complementary
DNA was synthesized using TaqMan Reverse Transcription Reagents
(Applied Biosystems, Foster City, CA). Quantitative RT-PCR was
performed, as described previously (Podgrabinska et al., 2002).
Primers for human VEGFR1, VEGFR3, LYVE-1, CCL21, and GAPDH
were as follows: VEGFR1 forward, 50-TCACTGCCACTCTAATTGTC-
30, and reverse, 50-CCATATGCGGTACAAGTCA-30; VEGFR3 for-
ward, 50-AAGGCGAGACCTGCATTC-30, and reverse, 50-CTGCCC
TCTTCTGAGCTCT-30; LYVE-1 forward, 50-GTTCCAGTGAGCCGAC
AGTT-30, and reverse, 50-TAAGGGGATGCCACCGAG TA-30;
CCL21 forward, 50-GGTTCTGGCCTTTGGCATC-30, and reverse,
50-AGGCAACAGTCCTGAGCCC-30; and GAPDH forward, 50-ACC
CACTCCTCCACCTTTGA-30, and reverse, 50-CATACCAGGAAATGA
GCTTGACAA-30.
Examination of CCL21 expression by HMVEC-dLy using
quantitative real-time RT-PCR and by ELISA
HMVEC-dLy at passages 3–6 were cultured in endothelial basal
medium-2 in the presence of microvascular endothelial cell growth
medium-2 without fetal bovine serum and stimulated for 24, 48, or
72 hours with OSM, IL-6, and IL-31 (1, 10, or 100 ng ml1). Cell
culture supernatants were collected for ELISA, and cells were
harvested for quantitative real-time RT-PCR. Immunoreactive CCL21
in supernatant was quantified by human CCL21 ELISA kit (R&D
systems). Quantitative RT-PCR was performed, as described above.
Signaling pathway protein expression by western blotting
HMVEC-dLy at passages 3–6 were cultured in endothelial basal
medium-2 in the presence of microvascular endothelial cell growth
medium-2 without fetal bovine serum and stimulated for 15 or
30 minutes with OSM, IL-6, and IL-31 (100 ng ml1). Cells were
lysed in RIPA buffer (Sigma-Aldrich, St Louis, MO) supplemented
with 1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl
fluoride, and 1 mM sodium fluoride. Samples were dissolved
in Electrophoresis Sample Buffer (Santa Cruz, Santa Cruz
Biotechnology, CA). SDS-PAGE was performed with Novex 10%
Tris-Glycine Gel (Invitrogen) and Novex Tris Gly SDS Running
Buffer (Invitrogen). After transfer to nitrocellulose membrane
(Invitrogen), the membrane was blotted with the primary Ab
overnight at 4 1C and with the appropriate secondary Ab for 1 hour
at room temperature. Visualization was performed by SuperSignal
West Pico Chemiluminescent Substrate (Pierce, Rockford, IL).
Inhibiting signaling pathways in vitro
HMVEC-dLy at passages 3–6 were cultured in endothelial basal
medium-2 in the presence of microvascular endothelial cell growth
medium-2 without fetal bovine serum and stimulated for 15,
30 minutes, or 48 hours with OSM (100 ng ml1), with or without
1 hour preincubation with JAK inhibitor 1 (500 nM), JAK3 inhibitor
(20 mM), and U0126 (5mM). We used highest dosages of signaling
pathway inhibitors that do not affect cell survival rate at 72 hours.
Cell culture supernatants were collected for ELISA, and cells were
lysed in RIPA buffer. Western blotting and ELISA were performed, as
described above.
Inhibiting signaling pathways in vivo
U0126 (100 mM, 20 ml) or DMSO was injected into the ear of C57BL/
6 mice. Twenty-four hours later, the ears were harvested. mRNA was
obtained by using illustra QuickPrep Micro mRNA Purification Kit
(GE Healthcare, Buckinghamshire, UK). The ears were also lysed in
RIPA buffer using homogenizer. Quantitative real-time RT-PCR and
western blotting were performed, as described above. Western blots
were quantitated densitometrically using image analysis software
(Image J, National Institutes of Health, Bethesda, MD), and CCL21
protein expression relative to b-actin was calculated. Primers for
mouse CCL21, CCR7, LYVE-1, and GAPDH were as follows: CCL21
forward, 50-ATCCCGGCAATCCTGTTCTT-30, and reverse, 50-GCCTT
CCTCAGGGTTTGCA-30; CCR7 forward, 50-GGACACGCTGAGATG
CTCACT-30, and reverse, 50-CCATCTGGGCCACTTGGAT-30; mouse
LYVE-1 forward, 50-TCCACCTTTGACCTCCAT-30, and reverse, 50-A
CTGAACCTGACCGTACATTGAATGCTGCTCCACTT-30; and GAP
DH forward, 50-CGTGTTCCTACCCCCAATGT-30, and reverse, 50-T
GTCATCATACTTGGCAGGTTTCT-30.
In vivo migration assay
U0126 (100mM, 20 ml) or DMSO was injected into the right ear of
C57BL/6 mice. Twenty-four hours later, mice were painted onto
right ear with 50 ml of 0.5% FITC. After another 24 hours, mice were
killed, and cervical LNs were collected, minced, and treated with
1 mg ml1 collagenase D (Roche, Basel, Switzerland) and 0.05%
DNase (Sigma-Aldrich) for 45 minutes at 37 1C. Cells were filtered,
washed, and resuspended in 0.1% BSA/PBS. Single-cell suspensions
were stained at 4 1C using phycoerythrin-conjugated anti-major
histocompatibility complex class II at predetermined optimal
concentrations for 20 minutes. Labeled cells were analyzed on an
EPICS XL flow cytometer (Beckman Coulter, Fullerton, CA), with
fluorescence intensity shown on a 4-decade log scale. Positive and
negative populations of cells were determined using unreactive
isotype-matched Abs (Southern Biotechnology, Birmingham, AL) as
controls for background staining.
Sensitization and elicitation of CHS
CHS responses were induced with DNFB (Sigma-Aldrich), as
previously described (Watanabe et al., 2007). Fifty microliter of
0.5% DNFB in 4:1 acetone/olive oil solution was painted onto right
ear on day 0, and CHS was elicited by applying 20 ml of 0.25%
DNFB on the left ear on day 5. In some experiments, U0126 (100 mM,
20 ml), anti-mouse CCL21 Ab (20 mg ml1, 20 ml), recombinant
mouse CCL21 (25 mg ml1, 20 ml), DMSO, or PBS was injected into
the right ear on day 1. In other experiments, each reagent was
injected into the left ear on day 5, and CHS was elicited on day 6.
For all CHS experiments, baseline ear thickness was determined with
a spring-loaded caliper. Ear swelling responses were measured with
a spring-loaded caliper at 24, 48, and 72 hours after elicitation, and
the change in ear thickness from baseline measurement was
computed. Each ear was measured three times and the mean of
these values was used. In some experiments, the ears were removed
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24 hours after challenge and assessed histologically. Ear skin samples
were fixed in 4% formalin and embedded. Sections, 4-mm thick,
were cut and stained with hematoxylin and eosin.
Statistical analysis
Statistical analysis between two groups was performed using the
Mann–Whitney U-test. A P-value of o0.05 was considered
statistically significant.
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